Adropin and irisin in arterial hypertension, diabetes mellitus and chronic kidney disease

Maciorkowska, Magdalena; Musiałowska, Dominika; Małyszko, Jolanta

doi:10.17219/acem/104551

Cited by 54 publications

(51 citation statements)

References 47 publications

(59 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Adropin was associated with a nondipping pattern, suggesting that adropin may be associated with increased target organ damage 51 . Reduced adropin levels were described in patients with hypertensive disorders complicating pregnancy (HDCP) 9,52 …”

Section: Adropin Regulates Biological Pathways That Are Directly or Imentioning

confidence: 99%

“…Adropin was also shown to play a role in the regulation of various systems that are directly or indirectly associated with its metabolic regulatory functions. [7][8][9] As such, adropin contributes to the pathogenesis of several diseases.…”

Section: Adropin Regulates Biological Pathways That Are Directly Ormentioning

confidence: 99%

“…51 Reduced adropin levels were described in patients with hypertensive disorders complicating pregnancy (HDCP). 9,52 In haemodialysis (HD) patients, reduced serum levels of adropin were associated with dyslipidemia. Major homozygotes of ENHO rs2281997 had increased serum adropin levels, whereas major homozygotes of RXRA (rs749759, rs10776909) showed decreased levels.…”

Section: Adropin Regulates Biological Pathways That Are Directly Ormentioning

confidence: 99%

“…[4][5][6] In this review, we explore the role of adropin, the ANS and the circadian rhythm in metabolic pathways and suggest a potential role for adropin as a mediator of the metabolic system-ANS axis. [7][8][9] We also present details of the possible establishment of an individualized adropin and circadian rhythm-based platform for implementing chronotherapy for improving therapy for various disorders.…”

mentioning

confidence: 99%

See 3 more Smart Citations

Adropin as a potential mediator of the metabolic system‐autonomic nervous system‐chronobiology axis: Implementing a personalized signature‐based platform for chronotherapy

2020

View full text Add to dashboard Cite

Adropin is a peptide hormone, which plays a role in energy homeostasis and controls glucose and fatty acid metabolism. Its levels correlate with changes in carbohydratelipid metabolism, metabolic diseases, central nervous system function, endothelial function and cardiovascular disease. Both metabolic pathways and adropin are regulated by the circadian clocks. Here, we review the roles of the autonomic nervous system and circadian rhythms in regulating metabolic pathways and energy homeostasis. The beneficial effects of chronotherapy in various systems are discussed. We suggest a potential role for adropin as a mediator of the metabolic system-autonomic nervous system axis. We discuss the possibility of establishing an individualized adropin and circadian rhythm-based platform for implementing chronotherapy, and variability signatures for improving the efficacy of adropin-based therapies are discussed. K E Y W O R D S adropin, autonomic nervous system, chronobiology, metabolic syndrome 1 | INTRODUCTION Metabolic syndrome (MetS) is a cluster of metabolic and cardiovascular complications, which increase the risk of cardiovascular diseases (CVD) and type 2 diabetes (T2D). 1 The pathogenesis of MetS involves multiple factors, including the autonomic nervous system (ANS) and the circadian rhythm. 2 Recently, MetS was also shown to increase the risk and mortality of cancer, 3 with which it shares many risk factors including age, genetic factors, obesity, physical inactivity, unhealthy diet, alcohol, smoking, endocrine disruptors exposure and air pollution. Recent studies have suggested that several peptide hormones play important roles in the modulation of systemic metabolism and energy homeostasis. Adropin is a product of the energy homeostasis associated (Enho) gene and a peptide hormone that plays a role in the regulation of energy homeostasis and controls glucose and fatty acid metabolism. It was originally described as a secreted peptide, with

show abstract

Section: Adropin Regulates Biological Pathways That Are Directly or Imentioning

confidence: 99%

Section: Adropin Regulates Biological Pathways That Are Directly Ormentioning

confidence: 99%

Section: Adropin Regulates Biological Pathways That Are Directly Ormentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Adropin as a potential mediator of the metabolic system‐autonomic nervous system‐chronobiology axis: Implementing a personalized signature‐based platform for chronotherapy

2020

View full text Add to dashboard Cite

show abstract

“…Accumulating evidence shows that irisin, a newly emerging adipokine, has been involved in the pathogenesis of T2DM [9]. A pre-vious meta-analysis including 23 studies showed that compared with non-diabetic controls, circulating irisin concentrations were significantly lower in patients with T2DM [10], suggesting a potential protective role of irisin for glycemic metabolism.…”

Section: Introductionmentioning

confidence: 99%

Association Between Serum Irisin and Diabetic Nephropathy in Patients with Type 2 Diabetes Mellitus: A Meta-Analysis

Wang

Liu

2021

Horm Metab Res

View full text Add to dashboard Cite

Irisin, an emerging adipokine, has been involved in the pathogenesis of type 2 diabetes mellitus (T2DM). However, previous studies evaluating the association between irisin and diabetic nephropathy (DN) showed inconsistent results. We performed a meta-analysis to evaluate the above association. Matched case-control studies evaluating the difference of serum irisin between T2DM patients with and without DN were identified via systematic search of PubMed, Embase, Cochranes’ Library, China National Knowledge Infrastructure, and WanFang databases from inception to December 5, 2020. A random-effects model or a fixed-effects model was used to pool the results according to the heterogeneity. Overall, thirteen matched case-control studies including 1735 T2DM patients were included. Results of meta-analysis showed that compared to T2DM patients with normoalbuminuria, those with microalbuminuria [10 studies, standard mean difference (SMD): 1.12, 95% confidence interval (CI): 0.48–1.77, p<0.001; I2=94%] and macroalbuminuria (10 studies, SMD: 1.86, 95% CI: 0.93–2.79, p<0.001; I2=97%) had significantly lower serum irisin. Besides, the serum level of irisin was significantly lower in T2DM patients with macroalbuminuria than those with microalbuminuria (10 studies, SMD: 0.91, 95% CI: 0.44–1.38, p<0.001; I2=90%). In addition, patients with estimated glomerular infiltration rate (eGFR)<60 ml/min 1.73 m2 had lower serum irisin compared to those with eGFR≥60 ml/min 1.73 m2 (4 studies, SMD: 0.89, 95% CI: 0.32–1.46, p=0.002; I2=91%). In conclusion, serum irisin may be associated with albuminuria and reduced eGFR in T2DM patients.

show abstract

Muskulatur: „peripheres mechanisch- und Signalstoff-gestütztes Zentrum der Gesundheit“

Laube

2023

Bewegungsmangel

View full text Add to dashboard Cite

Adropin and irisin in arterial hypertension, diabetes mellitus and chronic kidney disease

Cited by 54 publications

References 47 publications

Adropin as a potential mediator of the metabolic system‐autonomic nervous system‐chronobiology axis: Implementing a personalized signature‐based platform for chronotherapy

Adropin as a potential mediator of the metabolic system‐autonomic nervous system‐chronobiology axis: Implementing a personalized signature‐based platform for chronotherapy

Association Between Serum Irisin and Diabetic Nephropathy in Patients with Type 2 Diabetes Mellitus: A Meta-Analysis

Muskulatur: „peripheres mechanisch- und Signalstoff-gestütztes Zentrum der Gesundheit“

Contact Info

Product

Resources

About